Pharma boosts lobby spending in first quarter of 2019

pharmafile | April 24, 2019 | News story | Research and Development PhRMA, Trump, USA, congress, lobbying, lobbyists, pharma 

The Pharmaceutical Research and Manufacturers of America (PhRMA) trade lobbyists have spent near record levels on lobbying in the first three months of 2019.

According to disclosures filed to Congress, the US lobby group spent $9.91 million in the first quarter of 2019.

The figures show a moer than 50% increase on the final quarter of 2018, as spending increased from $6.03 million in the last three months of last year. In total PhRMA spent a record $27.5 million on lobbying in 2018.

Meanwhile AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Eli Lilly and Genentech were all shown to have increased spending on lobbying in the first three months of 2019.

While AstraZeneca were shown to have spent $1 million on lobbying in the first quarter of 2019, compared to $600,000 in the first quarter of last year, Bristol-Myers Squibb increased spending to $1.2 million from $800,000 last year.

US firms J&J and Eli Lilly boosted lobby money to $1.4 million while Genentech came out on top spending $3 million in the first quarter of 2019, compared to $1.7 million over the same period last year.

The extra spending comes amid the Trump administration’s pricing plan, which sets out to lower the price of drugs through price transparency and new rules for generic drugs. Meanwhile Congress has ramped up the pressure on price hiking firms.

Louis Goss

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content